PTEN level in tumor suppression: how much is too little?
The importance of PTEN (phosphatase and tensin homolog located on chromosome 10) in cancer has surpassed all predictions and expectations from the time it was discovered and has qualified this gene as one of the most commonly mutated and deleted tumor suppressors in human cancer. PTEN levels are frequently found downregulated in cancer, even in the absence of genetic loss or mutation. PTEN is heavily regulated by transcription factors, microRNAs, competitive endogenous RNAs (such as the PTEN pseudogene), and methylation, whereas the tumor suppressive activity of the PTEN protein can be altered at multiple levels through aberrant phosphorylation, ubiquitination, and acetylation. These regulatory cues are presumed to play a key role in tumorigenesis through the alteration of the appropriate levels, localization, and activity of PTEN. The identification of all these levels of PTEN regulation raises, in turn, a key corollary question: How low should PTEN level(s) or activity drop in order to confer cancer susceptibility at the organismal level? Our laboratory and others have approached this question through the genetic manipulation of Pten in the mouse. This work has highlighted the exquisite and tissue-specific sensitivity to subtle reductions in Pten levels toward tumor initiation and progression with important implications for cancer prevention and therapy.
Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Arkaitz
A
Carracedo
Andrea
A
Alimonti
Pier Paolo
PP
Pandolfi
D000818:Animals; D016147:Genes, Tumor Suppressor; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology; D051059:PTEN Phosphohydrolase / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism*
D051059:PTEN Phosphohydrolase
PLoS Biol. 2003 Dec;1(3):E59
14691534
J Biol Chem. 2003 Jul 25;278(30):28258-63
12743124
Nat Genet. 2008 Jan;40(1):102-7
18066063
Cancer Res. 2007 Nov 1;67(21):10343-50
17974977
Nature. 2006 May 25;441(7092):518-22
16633340
Nat Genet. 1998 Aug;19(4):348-55
9697695
J Cell Sci. 2006 Dec 15;119(Pt 24):5160-8
17158918
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1563-8
9990064
Genet Med. 2009 Oct;11(10):687-94
19668082
Nature. 2006 May 25;441(7092):475-82
16598206
Nat Genet. 1997 Apr;15(4):356-62
9090379
Melanoma Res. 2009 Aug;19(4):203-10
19478684
Nature. 2010 Jun 24;465(7301):1033-8
20577206
Cancer Res. 1998 Jan 15;58(2):204-9
9443392
Biochem Biophys Res Commun. 2009 Feb 13;379(3):721-5
19114034
Science. 1997 Mar 28;275(5308):1943-7
9072974
Cancer Biol Ther. 2010 Dec 1;10(11):1194-200
20980828
J Pathol. 2011 Jan;223(2):137-46
21125671
J Biol Chem. 2009 Oct 30;284(44):30159-66
19740742
Mol Cell Biol. 2004 Feb;24(3):1007-21
14729949
Curr Top Microbiol Immunol. 2010;347:135-68
20549475
Nature. 2005 Aug 4;436(7051):725-30
16079851
Cancer Lett. 2009 Feb 8;274(1):143-50
18996641
Cell. 2008 May 2;133(3):403-14
18455982
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
5279523
Nat Genet. 2010 May;42(5):454-8
20400965
Curr Opin Genet Dev. 2010 Feb;20(1):87-90
20006486